HIV gene therapy passes first safety check in tiny study
NCT ID NCT02390297
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study follows 11 people who previously received a gene therapy called Cal-1 for HIV. The goal is to watch for any delayed side effects over many years. Researchers will also check whether the modified cells are still present and active in the blood. It is a safety-only study, not designed to measure how well the therapy controls HIV.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Cal-1 (gene-modified CD4+ T cells and/or CD34+ stem cells)
What this could lead to
If successful, this could confirm that Cal-1 gene therapy is safe over many years, supporting its use as a long-term HIV control strategy.
What could go wrong
This is a very small follow-up study (11 people) focused only on safety, not on whether the treatment works. It cannot prove effectiveness, and rare side effects may still emerge later.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Quest Clinical Research
San Francisco, California, 94115, United States
-
UCLA CARE Center
Los Angeles, California, 90035, United States